Skip to content
Menu

Truist Securities Upgrades Evolent Health to Buy, Maintains Price Target to $6

Benzinga Newsdesk 14 hours ago

Analyst RatingsNewsUpgradesPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Truist Securities analyst Jailendra Singh upgrades Evolent Health (NYSE:EVH) from Hold to Buy and maintains the price target from $6 to $6.

Truist Securities analyst Jailendra Singh upgrades Evolent Health (NYSE:EVH) from Hold to Buy and maintains the price target from $6 to $6.

Read at benzinga.com